Intravesical Bacillus Calmette‐Guérin Treatment for Superficial Bladder Tumours

Sendo, Toshiaki; Hirano, Atsuyuki; Uekado, Yasunari; Kyoku, Inbou; H, Aoshi; Ohkawa, Tadashi

doi:10.1111/j.1464-410x.1989.tb05255.x

Cited by 12 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Since then, BCG has established itself as the most effective form of intravesical therapy for the prophylaxis and treatment of superficial bladder cancer. 3,4 However, several studies have suggested that the immune response cascade in the submucosa of the urinary bladder after intravesical BCG therapy is involved in the mechanism by which BCG prevents the proliferation of bladder cancer. 5,6 Previously, we noted a marked increase in the amount of urinary polymorphonuclear neutrophil leukocytes immediately after intravesical BCG instillation and indicated the involvement of a preinflammatory cytokine (granulocyte-macrophage colony-stimulating factor, GM-CSF) produced by active helper T cells, which could be induced by BCG in the submucosa of the urinary bladder.…”

Section: Introductionmentioning

confidence: 99%

Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy

et al. 2007

View full text Add to dashboard Cite

Aim:In order to clarify the initial step of the mechanism by which bacillus Calmette-Guérin (BCG) exhibits antitumor activity via the immune response induced in the bladder submucosa after intravesical BCG therapy for human bladder cancer, various cytokines secreted in the urine after BCG instillation were measured. Methods: After transurethral resection of bladder cancer, a 6-week course of BCG instillation was performed. At the first and sixth weeks' dosings, spontaneously excreted urine was collected before and 4, 8, and 24 h after BCG instillation. The urinary cytokines were determined by Sandwich enzyme-linked immunosorbent assay using monoclonal antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF)-a, granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-1b, IL-8, interferon (IFN)-g, and IL-12. Results: After the BCG therapy, various cytokines, such as GM-CSF, TNF-a, G-CSF, IL-1b, IL-8, IFN-g, and IL-12 were secreted , comprising the immune response cascade. The mean urinary excretions of GM-CSF and TNF-a 4 h after the sixth week's instillation were significantly higher than the pre-instillation levels. There were no significant increases in the urinary IFN-g or IL-12 levels between 4 and 24 h after the sixth week's instillation. The TNF-a level 4 h after the sixth week's instillation had a strong tendency towards the absence of recurrence, with a mean follow-up of 54.1 months. The Kaplan-Meier curve showed the 2, 5, and 10-year recurrence-free survival rates were 72.4%, 65.8%, and 56.4%, respectively. Conclusions: We suggested that the urinary levels of TNF-a might be essential in antitumor activity after BCG therapy and might play an important role in the prevention of bladder tumor recurrence.

show abstract

Section: Introductionmentioning

confidence: 99%

Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Different strains of BCG might have dissimilar effects. The reported efficient strains included Tice, Pasteur, Armand Frappier, and Tokyo 172 [26,27], In general the response rate was between 50 and 85% and the most frequent complica tions were chemical cystitis, hematuria, fever, and liver function impairment [28,29], Taipei-NIPM BCG in--4-.U Table 4. NK cell cytotoxicity in mice spleen after receiving 6 con-;quent weekly instillations of normal saline or BCG (5 mg/ml) withut prior cauterization of bladder 6 rophage, activated T cells, and HLA-DR antigen-acti vated cells [39] and monocytes [40].…”

Section: Resultsmentioning

confidence: 99%

Safety and Immunoresponse Study of Intravesical Instillation ofTaipei-IMIPM Bacillus Calmette-Guérin

Chang

Yü²,

Ma³

et al. 1992

Eur Urol

View full text Add to dashboard Cite

“…The most effective of these appeared to be BCG. Immunotherapy with BCG has been used with success, because the response rates range from 50 to 100% [2,6]. Since 1986, intravesical BCG immunotherapy has been used in our institute for prophylaxis after TUR of superficial bladder tumors with a high success rate.…”

Section: Discussionmentioning

confidence: 99%

“…Transurethral resection (TUR) with cystoscopic and cytological follow-up is the standard therapy for superficial bladder cancer. The major problems in the management of superficial bladder cancer are high recurrence rate and malignant progression after TUR [1,2]. Since multifocal field changes may contribute to the recurrence of bladder tumors, additional treatment might be appropriate to supplement the endo- scopic resection in certain patients.…”

Section: Introductionmentioning

confidence: 99%

Intravesical Combined Chemoimmunotherapy with Epirubicin and Bacillus Calmette-Guérin Is Not Indicated for Superficial Bladder Cancer

Tozawa

Okamura²,

Sasaki³

et al. 2001

Urol Int

View full text Add to dashboard Cite

Purpose: The short-term effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin (BCG) administered repeatedly for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 24 patients aged a median of 70 years between March 1996 and February 1999, and were compared with those of BCG monotherapy in 50 patients from March 1990 to February 1999. Patients and Methods: The patients underwent intravesical instillation of the Tokyo strain BCG with or without epirubicin after transurethral resection (TUR) of bladder cancer. For the combined treatment, at 1–2 weeks after TUR, epirubicin (40 mg) and BCG (80 mg) were istilled into the bladder by turns once a week for 12 weeks. For the group receiving only BCG, 80-mg instillations were done with the same schedule. Thereafter, the patients were followed by cystoscopy and urinary cytology every 3 months for up to 3 years after intravesical therapy. Results and Conclusions: At 2 years after treatment, the simple recurrence rate was 26.1% (6/23) in patients with chemoimmunotherapy and 32.0% (16/50) in BCG-treated patients. Adverse reactions, including increased frequency of urination, urgency and miction pain, were observed in 18 patients (85.7%) undergoing chemoimmunotherapy and 58.0% undergoing BCG monotherapy. One patient receiving chemoimmunotherapy was withdrawn from treatment because of symptoms of severe bladder irritation due to the instillation. Intravesical chemoimmunotherapy using epirubicin and BCG was finally found to be inferior in comparison with BCG monotherapy for the prophylaxis of recurrence of superficial bladder cancer.

show abstract

Intravesical Bacillus Calmette‐Guérin Treatment for Superficial Bladder Tumours

Cited by 12 publications

References 15 publications

Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy

Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy

Safety and Immunoresponse Study of Intravesical Instillation ofTaipei-IMIPM Bacillus Calmette-Guérin

Intravesical Combined Chemoimmunotherapy with Epirubicin and Bacillus Calmette-Guérin Is Not Indicated for Superficial Bladder Cancer

Contact Info

Product

Resources

About